组蛋白去乙酰化酶抑制剂抗卵巢癌的机制研究进展  

Research Advances in Mechanism of Histone Deacetylase Inhibitor for Treatment of Ovarian Cancer

作　　者：刘佳楠 唐芳兰 宁宁 王艳[1] LIU Jianan;TANG Fanglan;NING Ning;WANG Yan(Department of Gynecology,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院妇科,哈尔滨150001

出　　处：《医学综述》2018年第24期4842-4846,共5页Medical Recapitulate

摘　　要：组蛋白去乙酰化酶抑制剂(HDACI)能抑制组蛋白的去乙酰化修饰,改变核小体的空间结构,通过控制DNA缠绕于组蛋白的松紧程度发挥作用,达到调控肿瘤相关基因表达的目的。HDACI还可作用于一些非组蛋白底物,直接或间接调控很多生物过程,可显著抑制卵巢癌细胞的生长,并增敏铂类等药物的抗肿瘤作用。选择包含组蛋白去乙酰化酶抑制剂的联合抗肿瘤方案是国内外许多学者的研究热点。联合用药的治疗方案具有潜在的临床意义,有望在攻克复发性耐药性卵巢癌的治疗中发挥重要作用。Histone deacetylase inhibitor(HDACI)can inhibit histone deacetylation modification and change the spatial structure of nucleosome,so as to achieve the purpose of regulating the expression of tumor related genes by controlling the tightness of DNA around histone.HDACI also acts on a number of non-histone substrates and regulates many biological processes directly or indirectly,which can significantly inhibit the growth of ovarian cancer cells and enhance the anti-tumor effect of platinum and other drugs.The combination of anti-tumor drugs containing HDACI is the research focus of many scholars at home and abroad.The combination therapy has potential clinical significance and is expected to play an important role in the treatment of recurrent resistant ovarian cancer.

关 键 词：卵巢癌 组蛋白去乙酰化酶 组蛋白去乙酰化酶抑制剂 

分 类 号：R979.1[医药卫生—药品]